Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's 'Clear-Out' Strategy Sees Gout Drug Go To Grunenthal

Executive Summary

AstraZeneca is licensing its unlaunched gout drug Zurampic (lesinurad) out to privately held Grunenthal for sale in Europe and Latin America in the UK pure pharma's latest divesture of non-core assets amid efforts to focus on its central activities while also unlocking value from medicines in its portfolio.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q2 2016
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
Aspen Acquires AstraZeneca Anesthetics Portfolio Ex-US

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel